Last $4.08 USD
Change Today -0.02 / -0.49%
Volume 15.1K
IMNP On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
Frankfurt
Stockholm
As of 3:59 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

immune pharmaceuticals inc (IMNP) Snapshot

Open
$4.00
Previous Close
$4.10
Day High
$4.08
Day Low
$4.00
52 Week High
02/27/14 - $5.65
52 Week Low
09/19/13 - $1.15
Market Cap
65.8M
Average Volume 10 Days
52.3K
EPS TTM
$-1.45
Shares Outstanding
16.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNE PHARMACEUTICALS INC (IMNP)

immune pharmaceuticals inc (IMNP) Related Bloomberg News

View More Bloomberg News

immune pharmaceuticals inc (IMNP) Related Businessweek News

No Related Businessweek News Found

immune pharmaceuticals inc (IMNP) Details

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops targeted antibody therapeutics for the treatment of inflammatory diseases and cancer. Its lead product candidate includes Bertilimumab, a human monoclonal antibody that is under phase II clinical trial for the treatment of ulcerative colitis, as well as for the treatment of bullous pemphigoid, Crohn's disease, and severe asthma. The company’s product pipeline also comprise AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies that is under phase III clinical trials; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors under phase II clinical trials. In addition, its preclinical stage product candidate includes anti-ferritin combination gemcitabine-paclitaxel NanomAbs for the treatment of pancreatic and non-small cell lung cancer. Immune Pharmaceuticals, Inc. has strategic partnerships with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Dalhousie University; and Shire Biochem, Inc. The company is based in New York, New York.

immune pharmaceuticals inc (IMNP) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $112.7K
Compensation as of Fiscal Year 2013.

immune pharmaceuticals inc (IMNP) Key Developments

Immune Pharmaceuticals, Inc. Proposes Third Amended and Restated Certificate of Incorporation

Immune Pharmaceuticals, Inc. at its annual meeting of stockholders to be held on September 5, 2014, to approve a proposed amendment to third amended and restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of up to and including one-for-three, such ratio to be determined by board of directors, prior to the 2015 annual meeting of stockholders and subject to other conditions specified in this proxy statement.

Immune Pharmaceuticals, Inc. Appoints Cameron Durrant to Board of Directors

Immune Pharmaceuticals, Inc. appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee. Dr. Durrant is an accomplished biotech entrepreneur, marketer, financier, and a business and corporate development professional with a strong medical base as an MD. He has served as board chairman and director and operated as CEO or interim CEO, as well as CFO, for both private and public companies. Most recently, Dr. Durrant served as a corporate officer of Hi-Tech Pharmacal and CEO of the ECR division.

Immune Pharmaceuticals, Inc. Announces Executive Changes

On July 10, 2014, Dr. Isaac Kobrin resigned from his position as a member of the board of directors of Immune Pharmaceuticals Inc., effective immediately. Dr. Kobrin also resigned from his position as the chairperson of the Research and Development Committee. Mr. Cameron Durrant accepted the Company's offer to be appointed as a member of the board of directors, effective July 10, 2014. The Company's board of directors approved the appointment of Mr. Durrant as an independent director to fill the vacancy created by the resignation of Mr. Kobrin from the board of directors of the Company and to hold office as a Class II director until the 2015 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Durrant will serve on the Compensation Committee and Research and Development Committee of the board of directors of the Company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMNP:US $4.08 USD -0.02

IMNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.50 USD -0.02
View Industry Companies
 

Industry Analysis

IMNP

Industry Average

Valuation IMNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,638.8x
Price/Book 22.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,461.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE PHARMACEUTICALS INC, please visit www.immunepharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.